Overview

Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The Primary Objective is to show non inferiority in cardiac safety (i.e myocardial necrosis-MN- assessed by positive cardiac Troponin I -cTnI- ultrasensitive assay) of a Xenon based general anesthesia procedure in patients with elevated cardiac risk scheduled for atherosclerotic vascular surgery (i.e patient with Coronary Arteries Disease risk) when compared to sevoflurane based general anesthesia procedure, postoperatively up to 3 days.
Phase:
Phase 3
Details
Lead Sponsor:
Air Liquide Santé International
Collaborators:
BIOMNIS Central laboratory
Eurofins Biomnis
INFERENTIAL
MONITORING FORCE GROUP CROs
Treatments:
Sevoflurane
Xenon